

**Immunity, Volume 49**


## **Supplemental Information**

### **The Innate Immune Sensor NLRC3**

#### **Acts as a Rheostat that Fine-Tunes**

#### **T Cell Responses in Infection and Autoimmunity**

**Toru Uchimura, Yoshitaka Oyama, Meng Deng, Haitao Guo, Justin E. Wilson, Elena Rampanelli, Kevin D. Cook, Ichiro Misumi, Xianming Tan, Liang Chen, Brandon Johnson, Jason Tam, Wei-Chun Chou, W. June Brickey, Alex Petrucelli, Jason K. Whitmire, and Jenny P.Y. Ting**



**Supplement Figure 1. *Nlrc3*<sup>-/-</sup> mice show normal frequencies of T cells in spleen and thymus.** Related to Figure 1.

Splenic and thymic T cell subpopulations and their numbers were evaluated between wild type (WT) controls and *Nlrc3*<sup>-/-</sup> mice (n=5 for WT, n=5 for *Nlrc3*<sup>-/-</sup> mice).

(A) Percentage and total number of CD3<sup>+</sup>CD4<sup>+</sup>, CD3<sup>+</sup>CD8<sup>+</sup>, CD3<sup>+</sup>CD19<sup>+</sup> and CD3<sup>+</sup>NK1.1<sup>+</sup> cells in spleen.

(B) Percentage and total number of CD4<sup>-</sup>CD8<sup>-</sup> (DN), CD3<sup>+</sup>CD4<sup>+</sup>CD8<sup>+</sup>(CD3-DP), CD3<sup>+</sup>CD4<sup>+</sup>CD8<sup>+</sup> (CD3<sup>+</sup>DP), CD3<sup>+</sup>CD4<sup>+</sup> and CD3<sup>+</sup>CD8<sup>+</sup> cells in thymus.

(C) Percentage and total number of CD25<sup>-</sup>CD44<sup>+</sup> DN (DN1), CD25<sup>+</sup>CD44<sup>+</sup> DN (DN2), CD25<sup>+</sup>CD44<sup>-</sup> DN (DN3) and CD25<sup>-</sup>CD44<sup>-</sup>DN cells (DN4) in thymus.


(D) Flow cytometric analysis of CD4<sup>+</sup> and CD8<sup>+</sup> populations among CD3<sup>+</sup> cells in spleen, as used in (A).

(E) Flow cytometric analysis of CD4<sup>+</sup> and CD8<sup>+</sup> populations among CD3<sup>+</sup> cells in thymus, as used for (B).

(F) Flow cytometric analysis of CD25<sup>+</sup> and CD44<sup>+</sup> populations among CD4<sup>-</sup>CD8<sup>-</sup> cells in thymus, representative of (C).

Data are from one experiment representative of two experiments. Data are shown as mean ± SEM.

Statistical significance determined by unpaired t-test. \*P < 0.05, \*\*P < 0.01, \*\*\*P < 0.001.




**Supplement Figure 2. *Nlrc3*<sup>-/-</sup> CD8<sup>+</sup> cells show normal expression of activation markers *in vitro*.** Related to Figure 1.

CD8<sup>+</sup> T cells purified from wild type and *Nlrc3*<sup>-/-</sup> mice were stimulated with anti-CD3 (5 µg/ml) and anti-CD28 (2 µg/ml) antibodies and incubated for 0, 4, 24, 48 hrs. The percentage of CD8<sup>+</sup>CD25<sup>+</sup> and CD8<sup>+</sup>CD69<sup>+</sup> cells, and MFI of CD25 among CD8<sup>+</sup>CD25<sup>+</sup> cells and CD69 among CD8<sup>+</sup>CD69<sup>+</sup> cells were evaluated.

Data are from one experiment representative of two or three experiments. Data are shown as mean ± SEM.

Statistical significance determined by unpaired t-test. \*P < 0.05, \*\*P < 0.01, \*\*\*P < 0.001.



**Supplement Figure 3. *Nlrc3*<sup>-/-</sup> CD8<sup>+</sup> T cells express normal amounts of cytokine upon *in vitro* stimulation.**

Related to Figure 2.

CD8<sup>+</sup> T cells purified from wild type and *Nlrc3*<sup>-/-</sup> mice were stimulated with anti-CD3 (5  $\mu$ g/ml) and anti-CD28 (2  $\mu$ g/ml) antibodies and incubated for 0, 4, 24, 48 hrs.

(A) Percentage of CD8<sup>+</sup>IFN- $\gamma$ <sup>+</sup> T cells and the MFI of IFN- $\gamma$  among CD8<sup>+</sup>IFN- $\gamma$ <sup>+</sup> T cells.





(B) Percentage of CD8<sup>+</sup>TNF<sup>+</sup> T cells and the MFI of TNF among CD8<sup>+</sup>TNF<sup>+</sup> T cells.

(C) Percentage of CD8<sup>+</sup>IL-2<sup>+</sup> T cells and the MFI of IL-2 among CD8<sup>+</sup>IL-2<sup>+</sup> T cells.

(D) Quantitative PCR analysis of *Tnf* transcript in response to TLR agonists, IL-1 $\beta$  and anti-CD3 and anti-CD28.

Representative data from two or three experiments. Data are shown as mean  $\pm$  SEM.

Statistical significance determined by unpaired t-test. \*P < 0.05, \*\*P < 0.01, \*\*\*P < 0.001.



**Supplement Figure 4. WT and *Nlrc3*<sup>-/-</sup> CD8<sup>+</sup> T cells show similar amounts of proliferation.** Related to Figure 3.

(A) Naïve CD4<sup>+</sup> CD25<sup>lo</sup>CD44<sup>lo</sup> T cells isolated from wild type and *Nlrc3*<sup>-/-</sup> mice were CFSE-labeled and stimulated with anti-CD3 (2.5 and 5 µg/ml) and anti-CD28 (2 µg/ml) antibodies. The histograms show their CFSE fluorescence after 3 to 4 days of stimulation.


(B) CD8<sup>+</sup> T cells isolated from wild type and *Nlrc3*<sup>-/-</sup> mice were CFSE-labeled and stimulated with anti-CD3 (1, 2.5 and 5 µg/ml) and anti-CD28 (2 µg/ml) antibodies for 3 to 5 days. The histograms show CFSE fluorescence dilution for CD8<sup>+</sup> T cells.

(C) Number of cells recovered from the cultures in (B).

(D) CD4<sup>+</sup> T cells or CD8<sup>+</sup> T cells purified from WT and *Nlrc3*<sup>-/-</sup> mice were stimulated with anti-CD3 (5 µg/ml) and anti-CD28 (2 µg/ml) antibodies and incubated for 0, 4, 24, 48 hrs. Dead cells were identified by “Ghost Dye” fluorescent assay. Graphs show the percentage of CD4<sup>+</sup> and CD8<sup>+</sup> cells that were dead.

Results are representative of at least two experiments. Data are shown as mean ± SEM.

Statistical significance determined by unpaired t-test. \*P < 0.05, \*\*P < 0.01, \*\*\*P < 0.001.



**Supplement Figure 5. *Nlrc3*<sup>-/-</sup> mice show improved CD4<sup>+</sup> T cell responses during LCMV infection.** Related to Figures 4 and 5.


WT and *Nlrc3*<sup>-/-</sup> mice were given LCMV-Armstrong (A) or LCMV-Clone 13 (B) and T cell response were measured 8 days later.

(A) Percentage among all spleen cells of LCMV-specific DbGP33<sup>+</sup> CD8<sup>+</sup> cells (top) and LCMV-specific I-AbGP67<sup>+</sup> CD4<sup>+</sup> T cells (bottom) (n=4 for WT Uninfected, n=4 for *Nlrc3*<sup>-/-</sup> Uninfected, n=4 for WT with Armstrong infection, n=4 for *Nlrc3*<sup>-/-</sup> with Armstrong infection). Data are from one experiment representative of two independent experiments.

(B) Percentage among all spleen cells of LCMV-specific DbGP33<sup>+</sup> CD8<sup>+</sup> cells (top) and, LCMV-specific I-AbGP67<sup>+</sup> CD4<sup>+</sup> T cells (bottom) (n=3 for WT Uninfected, n=3 for *Nlrc3*<sup>-/-</sup> Uninfected, n=4 for WT with Clone 13 infection, n=4 for *Nlrc3*<sup>-/-</sup> with Clone 13 infection). Data are from one experiment representative of three independent experiments.

Each symbol represents one mouse. Data are shown as mean ± SEM.

Statistical significance determined by unpaired t-test. \*P < 0.05, \*\*P < 0.01.



**Supplement Figure 6. NLRC3 does not attenuate TCR proximal signals.** Related to Figure 7.

(A) Densitometric analysis of three composite p-ZAP70 immunoblots.

(B- C) Western blot analyses of isolated CD4<sup>+</sup> T cells from WT and *Nlrc3*<sup>-/-</sup> mice stimulated with anti-CD3 (5 $\mu$ g/ml) and anti-CD28 (2 $\mu$ g/ml) antibodies.







(D) MFI of p-STAT1, T-bet and Eomes in CD4<sup>+</sup> from 2D2 Tg<sup>+</sup> *Nlrc3*<sup>+/+</sup> or 2D2 Tg<sup>+</sup> *Nlrc3*<sup>-/-</sup> mice after co-culture with DCs.

(E) Densitometric analysis of p-mTOR, p-AKT and p-4EBP1 from three composite immunoblots.

Results are representative of at least two experiments. Data are shown as mean  $\pm$  SEM.

Statistical significance determined by unpaired t-test. \*P < 0.05, \*\*P < 0.01.





**Supplement Figure 7. NLRC3 suppress CD4<sup>+</sup> T cell metabolism in a NF- $\kappa$ B dependent manner.** Related to Figure 7.

(A) ECAR using isolated CD4<sup>+</sup> T cells from WT or *Nlrc3*<sup>-/-</sup> mice stimulated with anti-CD3 and anti-CD28 antibodies together with BAY11-7082 inhibitor (1 $\mu$ M) dissolved in DMSO or DMSO for 24 hrs. Cells were measured over time and exposed to glucose, oligomycin, 2-DG for ECAR measurement. Basal ECAR, glycolysis (ECAR rate after glucose addition), glycolytic capacity (maximal ECAR after subtracting the ECAR rate following 2-DG exposure) and glycolytic reserve (difference between oligomycin-induced maximal ECAR and glucose-induced glycolytic flux) calculated from Figure 7I.

(B) ECAR using isolated CD4<sup>+</sup> T cells from WT or *Nlrc3*<sup>-/-</sup> mice stimulated with anti-CD3 and anti-CD28 antibodies together with QNZ inhibitor (1 $\mu$ M or 10 $\mu$ M) dissolved in DMSO or DMSO for 24 hrs. Basal ECAR, glycolysis, glycolytic capacity and glycolytic reserve calculated from Figure 7J.

(C) CD4<sup>+</sup> T cells purified from WT and *Nlrc3*<sup>-/-</sup> mice were stimulated with anti-CD3 (5  $\mu$ g/ml) and anti-CD28 (2  $\mu$ g/ml) antibodies together with BAY11-7082 inhibitor (1 $\mu$ M) dissolved in DMSO or DMSO for 24 hrs. Dead cells were identified by "Ghost Dye" fluorescent assay. Graph shows the percentage of CD4<sup>+</sup> cells that were dead.

(D) Immunoblot analysis of p-p65 in the presence of the NF- $\kappa$ B inhibitor, BAY11-7082.

Data are from one experiment, representative of at least two independent experiments.

Data are shown as mean  $\pm$  SEM. Statistical significance determined by Student' s t-test. \*P < 0.05, \*\*P < 0.01, .